Our R&D strategy for a thriving product pipeline
As a global biopharmaceutical company with a focus on innovation and specialty care, Ipsen is building a strong and sustainable portfolio of medicines to meet patients’ and their healthcare teams’ needs. We prioritize best-in-class and first-in-class treatments in oncology, rare disease, and neuroscience – areas in which we have proven experience, global capabilities, and a strong network of partners.
Key facts
Investing heavily in R&D
€687m invested in R&D in 2024, sustaining a high-value pipeline.
Precision focus in 3 therapeutic areas
Since 2020, Ipsen has brought in more than 30 programs across our three focus areas of Oncology, Rare disease, and Neuroscience at every stage of development.
Investing in a strong future
Ipsen has been around for around 100 years and plan to be around for another 100. We have significant firepower to invest in the development of next-generation medicines through the pipeline.
Our expert teams and facilities
700 R&D colleagues span three global sites in France, the UK and the US, supported by dedicated research and manufacturing facilities worldwide – including state-of-the-art capabilities in Wrexham, UK to develop and produce neurotoxins.
End-to-end expertise
Ipsen executes across all stages and geographies, leveraging our global footprint, end-to-end capabilities, and scalable operations that flex to portfolio needs.
Building a high-value, sustainable pipeline
Disease Areas
Phase
| Therapy Area | Compound Name | Compound Type | Indication | Trial | Phases |
|---|---|---|---|---|---|
|
|
|
1
2
3
|
|||
|
|
|
1
2
3
|
|||
|
|
|
1
2
3
|
|||
|
|
|
1
2
3
|
|||
|
|
|
1
2
3
|
|||
|
|
|
1
2
3
|
|||
|
|
|
1
2
3
|
|||
|
|
|
1
2
3
|
|||
|
|
|
1
2
3
|
|||
|
|
|
1
2
3
|
|||
|
|
|
1
2
3
|
|||
|
|
|
1
2
3
|
|||
|
|
|
1
2
3
|
Information shown as of September 2025
| R2 | lenalidomide + rituximab |
| 2L | second line |
| FL | follicular lymphoma |
| 1L | first line |
| pLGG | pediatric low-grade gliomas |
| ERKi | ERK inhibitor of the MAPK pathway |
| RAFi | RAF inhibitor of the MAPK pathway |
| BA | Biliary Atresia |
| PBC | primary biliary cholangitis |
| PSC | primary sclerosing cholangitis |
| FOP | fibrodysplasia ossificans progressiva |
| GL | glabellar lines |
| FHL | forehead lines |
| LHL | lateral canthal lines |
| AUL | adult upper limb spasticity |
| Ax | aesthetics |
| Tx | therapeutics |
Our Partnerships
Ipsen are building a high-impact pipeline driven by external innovation. We seek to build purpose-led partnerships that boost our capacity to improve or extend the lives of people living with cancer, rare diseases and neurological conditions.
Learn moreClinical Trials
Ipsen are building a high-impact pipeline driven by external innovation. We seek to build purpose-led partnerships that boost our capacity to improve or extend the lives of people living with cancer, rare diseases and neurological conditions.